Book a meeting
DO-BO

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

Dive deep into the heart of French market access with Dr. Stefan Walzer and Dr. Benoit Salaun on this episode of the Map Podcast. As experts in their fields, they dissect the intricacies of the French healthcare system, focusing on medical device reimbursement, and revealing the critical steps to success in this competitive landscape.

This episode is a goldmine for healthcare professionals, medtech innovators, and market access strategists seeking to penetrate the French market effectively. Gain unparalleled insights into securing the optimal position and price for your medical device in France. Embark on your journey to mastering French market access with expert guidance—listen today!

Related

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)

By

Stefan Walzer

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

Is the EU “Launch Obligation” Really as Scary as It Sounds, Dr. Alexander Natz?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour?

By

Stefan Walzer

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]